EGFR-Mutant NSCLC Treatment
Jun 22, 2026
EGFR-Mutant NSCLC: From Targeted Therapy Breakthroughs to the Next Era of Precision Medicine
Summary Non-small cell lung cancer accounts for ~85% of all lung cancer cases, with incidence rising steadily. The EGFR-mutant NSCLC landscape has progressed from 1st/2nd-generation EGFR TKIs (limited by T790M resistance, poor CNS penetration, and toxicity) to more effective 3rd-generation TKIs, with osimert...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
